术前新辅助化疗对宫颈癌患者的疗效观察

Effect of preoperative neoadjuvant chemotherapy on cervical carcinoma

目的 探讨宫颈癌患者术前行新辅助化疗的价值. 方法 宫颈癌患者118例,手术前给予2个疗程联合化疗（即新辅助化疗,A组）;另选择手术前未接受化疗的102例宫颈癌患者作对照（B组）,比较两组患者生存率及并发症的发生情况. 结果 A组5年生存率（80.5%）高于B组（67.6%）（P＜0.01）.不同病理类型及有无放化疗患者5年生存率,A组均高于B组（均P＜0.05）.两组5年复发转移率差异有统计学意义（P＜0.05）. 结论 新辅助化疗对适宜手术切除的宫颈癌患者是有益的,能提高近期控制率、手术切除率及远期生存率,减少复发与转移,值得临床推广应用.

Objective To study the value of neoadjuvant chemotherapy in the treatment of cervical carcinoma. Methods A clinical prospective study was carried out from Jan.1997 to Dec.2003,118 patients with cervical carcinoma were given two cycles of combined chemotherapy before operation（neoadjuvant chemotherapy group,group A）.102 patients accepted surgery alone in our hospital from Jan.1997 to Dec.2003 were chosen as the comparison group（group B）.Survival rate and complications were observed and analysed. Results 5 year survival rate in group A was significantly higher than that in group B（P〈0.01）,The 5 year survival rate was significantly higher in group A than in group B,despite of different pathological types,with or without radiochemotherapy（P〈0.05）.The recurrent rate was lower in group A than that in group B,which show significant difference in the 5 year recurrent rate（P〈0.05）. Conclusion Neoadjuvant chemotherapy is an effective method for the treatment of cervical carcinoma in early stage.Because of satisfactory short-term control rate,excision rate,long-term survival rate and low recurrent and metastatic rate,neoadjuvant chemotherapy is worth popularizing in clinical treatment.